Ignite Creation Date:
2024-05-06 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03610321
Status:
UNKNOWN
Last Update Posted:
2020-07-30
First Post:
2018-07-26
Brief Title:
Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia
Sponsor:
First Affiliated Hospital of Harbin Medical University
Organization:
First Affiliated Hospital of Harbin Medical University
Study Overview
Official Title:
Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia
Status:
UNKNOWN
Status Verified Date:
2020-06
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dyslipidemia is an independent risk factor for cardiovascular events Statins have become the cornerstone for the prevention and treatment of atherosclerotic vascular diseases However after the comprehensive control of the traditional risk factors including unhealthy lifestyle hypercholesterolemia hypertension hyperglycemia and obesity there is still a high risk of residual cardiovascular disease in patients with dyslipidemia Triglyceride elevation is the most common type of dyslipidemia and constitutes an important component of cardiovascular residual risk
The geraniol has a variety of pharmacological effects such as anti-inflammatory antioxidant regulating cell apoptosis Recent studies have confirmed that geraniol plays an important role in regulating glucose and lipid metabolism and may have a synergistic role with statins Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment It can increase the defense ability of gastric mucosa by improving the prostaglandin level and the concentration of amino hexose in the gastric mucosa Geraniol is the main components of Gefarnate Tablets In the previous study the investigators found that geraniol induced autophagy through the SIRT1-AMPK-mTOR pathway and accelerated the degradation of triglycerides in liver cells thus reducing the level of triglyceride in the serum of high fat diet mice 6 patients with hyperlipidemia were received Gefarnate Tablets 100mg times 3 times per day A month later the levels of serum triglyceride total cholesterol and low density lipoprotein cholesterol were decreased significantly However the above results need to be confirmed by the larger clinical research
Therefore the aim of this study is to evaluate the effect of Gefarnate Tablets on blood lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with statins provide more options for the treatment of lipid lowering treatment reduce the risk of cardiovascular remnant and improve the long-term prognosis of the coronary heart disease patients with residual hypertriglyceridemia
The geraniol has a variety of pharmacological effects such as anti-inflammatory antioxidant regulating cell apoptosis Recent studies have confirmed that geraniol plays an important role in regulating glucose and lipid metabolism and may have a synergistic role with statins Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment It can increase the defense ability of gastric mucosa by improving the prostaglandin level and the concentration of amino hexose in the gastric mucosa Geraniol is the main components of Gefarnate Tablets In the previous study the investigators found that geraniol induced autophagy through the SIRT1-AMPK-mTOR pathway and accelerated the degradation of triglycerides in liver cells thus reducing the level of triglyceride in the serum of high fat diet mice 6 patients with hyperlipidemia were received Gefarnate Tablets 100mg times 3 times per day A month later the levels of serum triglyceride total cholesterol and low density lipoprotein cholesterol were decreased significantly However the above results need to be confirmed by the larger clinical research
Therefore the aim of this study is to evaluate the effect of Gefarnate Tablets on blood lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with statins provide more options for the treatment of lipid lowering treatment reduce the risk of cardiovascular remnant and improve the long-term prognosis of the coronary heart disease patients with residual hypertriglyceridemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None